文献速递前列腺癌

17基因面板GPS在非裔与欧裔美国男性根治性前列腺切除术后不良病理预测中准确性相似

A 17-Gene Panel Genomic Prostate Score Has Similar Predictive Accuracy for Adverse Pathology at Radical Prostatectomy in African American and European American Men.
PubMed 文献 · Urology · 2020-04-08

本研究基于两项多中心观察性研究,纳入96例非裔美国(AA)和76例欧裔美国(EA)男性,验证Oncotype DX基因组前列腺评分(GPS)对根治性前列腺切除术后不良病理(AP)的预测作用。结果显示GPS是AP的显著预测因子(AA:OR/20单位=4.58,95%CI 1.8-11.5,P=.001;EA:OR/20单位=4.88,95%CI 1.8-13.5,P=.002),且GPS与种族无显著交互作用(P>.10),AUC在AA为0.69、EA为0.74(P=.79),GPS分布无种族差异(P>.05)。结论认为GPS在AA和EA男性中预测准确性及分布相似。

要点

  • GPS是AA和EA男性根治性前列腺切除术后AP的独立预测因子。
  • GPS预测AP的准确性在AA与EA男性间无显著差异(AUC 0.69 vs 0.74,P=.79)。
  • GPS分布无种族差异(P>.05),支持在AA男性中应用GPS。

核心结论

  • Oncotype DX GPS是AA和EA男性前列腺切除术后AP的独立预测因子,预测准确性和分布相似。

研究设计与样本

  • 基于两项多中心观察性研究,纳入2009年2月至2014年9月间接受≥10针经直肠超声引导活检后立即行根治性前列腺切除术的96例AA和76例EA男性。

主要发现

  • 总体46例(26.7%)出现AP。
  • GPS每20单位对AP的OR在AA为4.58(95%CI 1.8-11.5,P=.001),在EA为4.88(95%CI 1.8-13.5,P=.002)。
  • GPS与种族无显著交互作用(P>.10),校正NCCN风险组或CAPRA评分后GPS仍显著。
  • 种族分层模型中GPS/20单位的AUC在AA为0.69、EA为0.74(P=.79)。
  • GPS分布无种族差异(所有P>.05)。

关键数值与推荐

  • AP定义为根治性前列腺切除术后主要Gleason分级4、存在任何Gleason 5模式、和/或非器官局限性疾病(≥pT3aN0M0)。

临床怎么用

  • GPS可用于AA和EA男性局限性前列腺癌的风险分层,预测不良病理的准确性相似。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To validate the 17-gene Oncotype DX Genomic Prostate Score (GPS) as a predictor of adverse pathology (AP) in African American (AA) men and to assess the distribution of GPS in AA and European American (EA) men with localized prostate cancer. METHODS: The study populations were derived from 2 multi-institutional observational studies. Between February 2009 and September 2014, AA and EA men who elected immediate radical prostatectomy after a ≥10-core transrectal ultrasound biopsy were included in the study. Logistic regressions, area under the receiver operating characteristics curves (AUC), calibration curves, and predictive values were used to compare the accuracy of GPS. AP was defined as primary Gleason grade 4, presence of any Gleason pattern 5, and/or non-organ-confined disease (≥pT3aN0M0) at radical prostatectomy. RESULTS: Overall, 96 AA and 76 EA men were selected and 46 (26.7%) had AP. GPS result was a significant predictor of AP (odds ratio per 20 GPS units [OR/20 units] in AA: 4.58; 95% confidence interval (CI) 1.8-11.5, P = .001; and EA: 4.88; 95% CI 1.8-13.5, P = .002). On multivariate analysis, there was no significant interaction between GPS and race (P >.10). GPS remained significant in models adjusted for either National Comprehensive Cancer Network (NCCN) risk group or Cancer of the Prostate Risk Assessment (CAPRA) score. In race-stratified models, area under the receiver operating characteristics curves for GPS/20 units was 0.69 for AAs vs 0.74 for EAs (P = .79). The GPS distributions were not statistically different by race (all P >.05). CONCLUSION: In this clinical validation study, the Oncotype DX GPS is an independent predictor of AP at prostatectomy in AA and EA men with similar predictive accuracy and distributions.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Murphy AB, Carbunaru S, Nettey OS, et al. A 17-Gene Panel Genomic Prostate Score Has Similar Predictive Accuracy for Adverse Pathology at Radical Prostatectomy in African American and European American Men. Urology. 2020. PMID: 32277993. doi:10.1016/j.urology.2020.01.052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。